

Nanobodies® – Powerful platform generating innovative drug candidates

Ablynx is dedicated to creating new medicines which will make a real difference to society. The Company develops Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments. Due to their small size and unique structure, Nanobodies offer multiple advantages making them ideal building blocks for the generation of novel highly potent biological drugs. Ablynx has over 45 proprietary and partnered programmes in development across various therapeutic areas including inflammation, haematology, immuno-oncology and respiratory disease. The Company has collaborations with multiple leading pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals, which have generated >€450M in non-dilutive cash to date and that have the potential to deliver >€10Bn in future milestones plus royalties.


Rapid generation of novel biologics



Immunise llamas with antigen and/or use proprietary synthetic Nanobody phage libraries



Generate a wide range of highly diverse Nanobodies with 0.1-10nM affinities




Specifically formatted Nanobodies




Cloned into microbial systems and produced through fermentation

12-18 months

Derived from heavy-chain only antibodies



Conventional antibodies



Heavy chain only antibodies

Ablynx's Nanobody

- small and robust
- easily linked together
- sequence homology comparable to humanised/human mAbs
- nano- to picomolar affinities
- able to bind and block challenging targets
- multiple administration routes
- manufacturing in microbial cells

Corporate highlights

- Proprietary platform: unique, powerful and broadly validated next generation biologics platform with >500 granted and pending patents
- Broad product pipeline: >45 wholly-owned and partnered programmes; 8 Nanobodies in clinical development; first potential product commercialisation in 2018
- Clinical data: Phase I/II clinical proof-of-concepts for 5 Nanobodies achieved; supportive safety profile in >1,500 patients
- Partners: multiple discovery and drug development partnerships with top tier pharma companies
- Cash position: €205M in cash at 30 June 2017
- Corporate: founded in 2001; IPO in 2007 (Euronext Brussels); ~400 staff in Ghent, Belgium

Team


Board of Directors:
 Peter Fellner, Chairman
 Edwin Moses, CEO
 Russell G. Greig
 Bo Jesper Hansen
 William Jenkins
 Catherine Moukheibir
 Lutgart Van den Berghe
 Remi Vermeiren
 Hilde Windels

Executive Management:
 Edwin Moses, CEO
 Antonin de Fougères, CSO
 Robert K. Zeldin, CMO
 Wim Ottevaere, CFO
 Johan Heylen, CCO
 Markus Ewert, CBO
 Guido Gielen, VP HR
 Frank Landolt, VP IP & Legal

Investment case

- Unique and validated technology platform generating innovative drug candidates in a wide range of therapeutic areas, utilising different routes of administration
- Well funded business supporting the development of >45 programmes, both wholly owned and in partnership, offering a balanced risk/reward profile
- Company has the potential to launch its first product in 2018, caplacizumab, a first-in-class therapy for acquired thrombotic thrombocytopenic purpura in an estimated €800M market
- Multiple partnerships with pharmaceutical companies that have the potential to generate >€10Bn in non-dilutive cash plus royalties on net sales
- Strong pipeline with numerous short and medium term pre-clinical, clinical and regulatory catalysts expected from the proprietary and partnered programmes

Diversified Shareholder Base – Break down of share capital



- Ordinary shares listed on Euronext (ABLX)
- Sponsored Level I ADRs on the US OTC market (ABYLY)
- 61.4M shares outstanding
- 2.6M outstanding warrants (in number of shares)

5-year share price performance:



Hybrid business model fuels the product pipeline: >45 programmes, 8 Nanobodies in the clinic, 9 partners

Product	Indication	Target	Pre-clinical	Phase I	Phase II	Phase III	Filing	Catalysts	Partners
caplacizumab	aTTP	wWF	█	█	█	█	★	BLA filing H1 2018	Ablynx
vobarilizumab	RA SLE	IL-6R IL-6R	█	█	█	█		SLE Phase II data H1 2018	Ablynx, abbvie
ALX-0171	RSV	RSV	█	█	█	█		Phase IIb data H2 2018	Ablynx
Up to 17 programmes	Immuno-Oncology	Various	█						MERCK
Up to 8 programmes	Immuno-Inflammation	Various	█						SANOFI
ozoralizumab	RA RA	TNFα TNFα	█	█	█	Japan			TAISHO, EDDING
ALX-0761/M1095	Psoriasis	IL-17A/IL-17F	█	█	█				MERCK
ALX-1141/M6495	Osteoarthritis	ADAMTS-5	█	█	█				MERCK
BI 836880	Oncology	VEGF/Ang2	█	█	█				Boehringer Ingelheim
BI 655088	Chronic kidney disease	CX3CR1	█	█	█				Boehringer Ingelheim
ALX-0141	Bone disorders	RANKL	█	█	█	Greater China			Boehringer Ingelheim
>20 wholly-owned and partnered programmes			█						Boehringer Ingelheim, Ablynx

★ Filing in EU based on Phase II TITAN data

Contact details

Lies Vanneste, Director Investor Relations
 Ablynx nv, Technologiepark 21, 9052 Ghent/Zwijnaarde, Belgium
 Telephone: +32 (0)9 262 01 37
 E-Mail: investors@ablynx.com

Media & analyst relations

Consilium Strategic Communications:
 Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
 Telephone: +44 20 3709 5700
 E-Mail: ablynx@consilium-comms.com